Press release Biocartis Group NV: Biocartis and Ophiomics to Collaborate on Liver Cancer Test
February 08, 2022 01:00 ET | Biocartis NV
PRESS RELEASE: 8 February 2022, 07:00 CET Biocartis and Ophiomics to Collaborate on Liver Cancer Test Primary liver cancer1 is the sixth most common and third most lethal cancer in the...
Persbericht Biocartis Group NV: Biocartis en Ophiomics gaan samenwerken op test voor leverkanker
February 08, 2022 01:00 ET | Biocartis NV
PERSBERICHT: 8 februari 2022, 07:00 CET Biocartis en Ophiomics gaan samenwerken op test voor leverkanker Primaire leverkanker1 is de zesde meest voorkomende en derde meest dodelijke vorm van kanker...
22157.jpg
Global Interventional Oncology Devices Market, 2021-2030: Opportunities in the Emergence of Local Companies in Asia-Pacific and the Middle East and Africa
December 06, 2021 06:43 ET | Research and Markets
Dublin, Dec. 06, 2021 (GLOBE NEWSWIRE) -- The "Interventional Oncology Devices Market Analysis and Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering. The global...
Global Liver Institute Applauds Congresswoman Velázquez and Senator Duckworth for Bold Action on Liver Cancer
October 22, 2021 10:12 ET | Global Liver Institute
Washington, DC, USA, Oct. 22, 2021 (GLOBE NEWSWIRE) -- (Washington, DC, Friday, October 22, 2021)—Global Liver Institute (GLI) CEO and President, Donna R. Cryer, JD,  yesterday applauded the actions...
New Logo.png
Provectus Biopharmaceuticals Provides Update on Research into Oral Administration of PV-10® Immunotherapy for Treatments of Hematology, Oncology, and Virology
October 04, 2021 09:00 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided an update on the Company’s research into the systemic administration of Provectus’ investigational...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit
September 05, 2021 06:15 ET | Adaptimmune Therapeutics plc
- One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff - - Data presented today at the International Liver Cancer...
22157.jpg
Global $196.96 Bn Oncology Devices Market to 2025 & 2030: Major Players are Eckert & Ziegler BEBIG, Oncura, GE, Medtronic, Varian Medical Systems, Elekta, Theragenics, Accuray, and Roche Diagnostics
August 20, 2021 06:08 ET | Research and Markets
Dublin, Aug. 20, 2021 (GLOBE NEWSWIRE) -- The "Oncology Devices Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. The global...
Yiviva_Logo_(R)_1024px_300dpi.png
Yiviva Wins 2 Top Awards at SAPA Investment Forum and Road Show for Innovative Systems Biology Approach to Treat Cancer
July 30, 2021 08:00 ET | Yiviva
NEW YORK and SHANGHAI, China, July 30, 2021 (GLOBE NEWSWIRE) -- Yiviva, a clinical-stage biotechnology company that uses a systems-biology approach to treat aging-associated diseases, won two top...
22157.jpg
Global $3.32 Bn Interventional Oncology Devices Market to 2030: Embolization Devices, Ablation Devices, & Support Devices
July 16, 2021 05:53 ET | Research and Markets
Dublin, July 16, 2021 (GLOBE NEWSWIRE) -- The "Interventional Oncology Devices Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's...
Reports and Data.jpeg-01
Computer Aided Detection (CAD) Market to Reach USD 1579.5 Million In 2028 | Reports and Data
June 09, 2021 09:00 ET | Reports and Data
New York, June 09, 2021 (GLOBE NEWSWIRE) -- Rising prevalence of chronic diseases and growing demand for computational assistance are key factors surging global market growth  Market size: USD...